Showing 1161-1170 of 1287 results for "".
- Daily Imaging Boosts NMSC Treatment Success: Analysishttps://practicaldermatology.com/news/daily-imaging-boosts-nmsc-treatment-success-analysis/2468003/Image-guided superficial radiation therapy (IGSRT) was associated with a 99% cure rate for non-melanoma skin cancer (NMSC) when delivered with daily imaging, which allows for adaptive changes based on tumor depth fluctuations. Researchers for a recent retrospective study looked at the rol
- Review: No Safety Concerns for Live Vaccines with Dupilumabhttps://practicaldermatology.com/news/systematic-review-no-safety-concerns-live-vaccines-dupilumab/2467944/Live vaccines are likely safe and effective for patients undergoing dupilumab treatment, according to results from a systematic review and expert consensus. Authors for a new systematic review, combined with expert input from a Delphi panel, provided insights into the safety and efficacy o
- DermTech Files for Voluntary Chapter 11 Protectionhttps://practicaldermatology.com/news/dermtech-files-voluntary-chapter-11-protection/2467087/DermTech announced it has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company’s strategic alternatives review process. DermTech, which is a provider of noninvasive skin genomics technol
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Antibiotic-induced Acute Generalized Exanthematous Pustulosis: A Case Study of an 18-year-old Pregnant Female Presenting with Fever, Tachycardia, and Pustular Skin Eruptionhttps://practicaldermatology.com/news/antibiotic-induced-acute-generalized-exanthematous-pustulosis-a-case-study-of-an-18-year-old-pregnant-female-presenting-with-fever-tachycardia-and-pustular-skin-eruption/2462046/On the day of giving birth via vaginal delivery complicated by intrauterine fetal demise, an 18-year-old female, G1P000, developed preeclampsia with severe features. The patient subsequently developed chorioamnionitis and was started on ampicillin-gentamicin. After administration of the antibioti
- Time Matters When Saving Skin During FLASH Radiotherapyhttps://practicaldermatology.com/news/time-matters-when-saving-skin-during-flash-radiotherapy/2461966/Multiple beams and intervals in delivery during FLASH proton therapy treatment may reduce skin-saving effects in preclinical models, according to a study in the International Journal of Radiation
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Study Uncovers How B Cells React to Melanomahttps://practicaldermatology.com/news/study-uncovers-how-b-cells-react-to-melanoma/2461773/Antibody-producing B cells may be defective in responding to melanoma, a new study suggests. The study is published in Nature Communications. Researchers used advanced technologies to delve into the antibody immune response in blood and tissues of patients with m
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- U.S. FDA: Renuvion Cleared to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissuehttps://practicaldermatology.com/news/us-fda-renuvion-cleared-to-coagulate-and-contract-soft-tissues-including-subcutaneous-tissue/2461590/The U.S. Food and Drug Administration (FDA) has cleared the use of the Renuvion APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. (Soft tissue includes subcutaneous tissue.) “We are pleas